92807-01-7

Basic information

• Product Name: 2H-Benzimidazole-2-thione,1,3-dihydro-5-(hydroxymethyl)-(9CI)
• Synonyms: 2H-Benzimidazole-2-thione,1,3-dihydro-5-(hydroxymethyl)-(9CI)
• CAS NO: 92807-01-7
• Molecular Formula: C₈H₈N₂OS
• Molecular Weight: 180.22692
• Product Categories: BENZIMIDAZOLE
• Mol File: 92807-01-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Benzimidazole-2-thione,1,3-dihydro-5-(hydroxymethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazole-2-thione,1,3-dihydro-5-(hydroxymethyl)-(9CI)(92807-01-7)
• EPA Substance Registry System: 2H-Benzimidazole-2-thione,1,3-dihydro-5-(hydroxymethyl)-(9CI)(92807-01-7)

Safety Data

• Hazardous Substances Data: 92807-01-7(Hazardous Substances Data)

Usage

Structure

Heterocyclic compound containing a benzimidazole ring and a thione group

Uses

Commonly used in pharmaceutical research
Precursor or intermediate in the synthesis of various bioactive compounds
Potential pharmacological properties, including antiviral, antimicrobial, and antitumor activities
Derivatives being studied for potential as drug candidates for various diseases
Used in the production of specialty chemicals and in organic synthesis.

Upstream product

• 63189-98-0 1,2-diamino-4-hydroxymethylbenzene 
• 140-89-6 potassium ethyl xanthogenate 
• 17012-22-5 methyl 4-acetamidobenzoate 
• 73166-06-0 4-(hydroxymethyl)-2-nitroacetanilide 
• 6313-39-9 4-acetamido-3-nitro-benzoic acid methyl ester 
• 63189-97-9 (4-amino-3-nitrophenyl)methanol 
• 556-08-1 p-(acetylamino)benzoic acid 
• 64375-41-3 methyl 2-mercaptobenzimidazole-5-carboxylate 

Downstream Products

• 299901-34-1 5-(t-butyldiphenylsilyloxymethyl)-2-mercaptobenzoimidazole 
• 128429-80-1 [2-(4-Methoxy-3-methyl-pyridin-2-ylmethylsulfanyl)-1H-benzoimidazol-5-yl]-methanol 

Relevant articles and documents

1-N-AMINOBENZIMIDAZOLE DERIVATIVES

Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I): wherein R1 and R2 each represents a substituted or unsubstituted alkyl group or the like, R3, R5 and R6 each represents an alkyl group, alkoxy group, hydrogen atom or the like, R4 represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them. The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family. Accordingly, they are useful as peptic ulcer therapeutic agents which are safe and surely bring about therapeutic effects.